Literature DB >> 33099664

Serotonin 1A agonist and cardiopulmonary improvements with whole-body exercise in acute, high-level spinal cord injury: a retrospective analysis.

Isabelle Vivodtzev1,2,3, Glen Picard4, Kevin O'Connor5,4, J Andrew Taylor5,4.   

Abstract

PURPOSE: High-level spinal cord injury (SCI) can result in spinal and supraspinal respiratory control deficits leading to insufficient ventilatory responses to exercise and training-related adaptations. We hypothesized a serotonin agonist, known to improve respiratory function in animal models, would improve adaptations to whole-body functional electrical stimulation (FES) exercise training in patients with acute high-level SCI.
METHODS: We identified 10 patients (< 2 years of injury with SCI from C4 to T3) in our program who had performed 6 months of FES-row training while on Buspirone (29 ± 17 mg/day) between 2012 and 2018. We also identified well-matched individuals who trained for six months but not on Buspirone (n = 11). A peak incremental FES-rowing exercise test and resting pulmonary function test had been performed before and after training.
RESULTS: Those on Buspirone demonstrated greater increases in peak oxygen consumption (VO2peak: + 0.24 ± 0.23 vs. + 0.10 ± 0.13 L/min, p = 0.08) and peak ventilation (VEpeak: + 6.5 ± 8.1 vs. - 0.7 ± 6.9 L/min, p < 0.05) compared to control. In addition, changes in VO2peak and VEpeak were correlated across all patients (r = 0.63, p < 0.01), but most strongly in those on Buspirone (r = 0.85, p < 0.01). Furthermore, changes in respiratory function correlated with increased peak tidal volume in the Buspirone group (r > 0.66, p < 0.05).
CONCLUSION: These results suggest Buspirone improves cardiorespiratory adaptations to FES-exercise training in individuals with acute, high-level SCI. The strong association between increases in ventilatory and aerobic capacities suggests improved respiratory function is a mechanism; however, controlled studies are needed to determine if this preliminary finding is reproducible.

Entities:  

Keywords:  Aerobic capacity; Pulmonary function; Serotonin agonist; Spinal cord injury; Whole-body exercise

Mesh:

Substances:

Year:  2020        PMID: 33099664      PMCID: PMC7864870          DOI: 10.1007/s00421-020-04536-w

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  37 in total

1.  Spirometry testing standards in spinal cord injury.

Authors:  Alyson Kelley; Eric Garshick; Erica R Gross; Steven L Lieberman; Carlos G Tun; Robert Brown
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

2.  Buspirone in Rett syndrome respiratory dysfunction.

Authors:  Daniela K Andaku; Marcos T Mercadante; José Salomão Schwartzman
Journal:  Brain Dev       Date:  2005-09       Impact factor: 1.961

3.  Relationship between pulmonary function and exercise capacity in individuals with spinal cord injury.

Authors:  Maya Battikha; Luis Sà; Aidan Porter; J Andrew Taylor
Journal:  Am J Phys Med Rehabil       Date:  2014-05       Impact factor: 2.159

4.  Spinal activation of serotonin 1A receptors enhances latent respiratory activity after spinal cord injury.

Authors:  M Beth Zimmer; Harry G Goshgarian
Journal:  J Spinal Cord Med       Date:  2006       Impact factor: 1.985

5.  Mechanism of active expiration in tetraplegic subjects.

Authors:  A De Troyer; M Estenne; A Heilporn
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

6.  Respiratory abnormalities resulting from midcervical spinal cord injury and their reversal by serotonin 1A agonists in conscious rats.

Authors:  Howard Choi; Wei-Lee Liao; Kimberly M Newton; Renna C Onario; Allyson M King; Federico C Desilets; Eric J Woodard; Marc E Eichler; Walter R Frontera; Sunil Sabharwal; Yang D Teng
Journal:  J Neurosci       Date:  2005-05-04       Impact factor: 6.167

7.  Respiratory system determinants of peripheral fatigue and endurance performance.

Authors:  Jerome A Dempsey; Markus Amann; Lee M Romer; Jordan D Miller
Journal:  Med Sci Sports Exerc       Date:  2008-03       Impact factor: 5.411

Review 8.  Buspirone: Back to the Future.

Authors:  Robert H Howland
Journal:  J Psychosoc Nurs Ment Health Serv       Date:  2015-11       Impact factor: 1.098

Review 9.  Respiratory muscles and ventilatory failure: 1993 perspective.

Authors:  D F Rochester
Journal:  Am J Med Sci       Date:  1993-06       Impact factor: 2.378

10.  Buspirone treatment for apneustic breathing in brain stem infarct.

Authors:  Mohamad F El-Khatib; Rabee A Kiwan; Ghassan W Jamaleddine
Journal:  Respir Care       Date:  2003-10       Impact factor: 2.258

View more
  1 in total

Review 1.  Serotonin 1A Receptor Pharmacotherapy and Neuroplasticity in Spinal Cord Injury.

Authors:  Afaf Bajjig; Florence Cayetanot; J Andrew Taylor; Laurence Bodineau; Isabelle Vivodtzev
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.